NHI.no
Annonse
Informasjon

Malignt nevroleptikasyndrom

Malignt nevroleptikasyndrom er en komplikasjon til behandling med antipsykotika. Typiske tegn er endret mental status, muskelstivhet, ufrivillige bevegelser og feber.

Malignt nevroleptikasyndrom behandles ved å stanse inntaket av den utløsende medisinen.

Sist oppdatert:

10. feb. 2022

Dette dokumentet er basert på det profesjonelle dokumentet Malignt nevroleptikasyndrom . Referanselisten for dette dokumentet vises nedenfor

  1. Ware MR, Feller DB, Hall KL. Neuroleptic Malignant Syndrome: Diagnosis and Management. Prim Care Companion CNS Disord. 2018;20(1):17r02185. Published 2018 Jan 4. PMID: 29325237 PubMed
  2. Dietrichs ES, Dietrichs E. Time to replace the term neuroleptic malignant syndrome with antidopaminergic syndrome?. Lancet Psychiatry 2022. doi:10.1016/S2215-0366(22)00108-0 DOI
  3. Wijdicks EFM. Neuroleptic malignant syndrome. UpToDate, last updated May 31, 2019. UpToDate
  4. Perry PJ, Wilborn CA. Serotonin syndrome vs neuroleptic malignant syndrome: a contrast of causes, diagnoses, and management. Ann Clin Psychiatry 2012;24:155-162. PubMed
  5. Benzer TI. Neuroleptic malignant syndrome. Medscape, last updated Feb 12, 2015. emedicine.medscape.com
  6. Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. Ann Pharmacother 2008;42;1290-1297.
  7. Croarkin PE, Emslie GJ, Mayes TL. Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. J Clin Psychiatry 2008;69:1157-1165. PubMed
  8. Rosebush PI, Anglin RE, Richards C, et al. Neuroleptic malignant syndrome and the acute phase response. J Clin Psychopharmacol 2008;28:459-461. PubMed
  9. Viejo LF, Morales V, Puñal P, Pérez JL, Sancho RA. Risk factors in neuroleptic malignant syndrome: A case-control study. Acta Psychiatr Scand 2003; 107: 45-49. PubMed
  10. Mitchell J, Jenkins-Welch M. Neuroleptic malignant syndrome. BMJ Best Practice, last updated 08 Sept, 2021.
  11. Helsedirektoratet. Nasjonal faglig retningslinje om bruk av elektronkonvulsiv behandling - ECT. IS-2629. Oslo: Helsedirektoratet 2017. helsedirektoratet.no
  12. Ozer F, Meral H, Aydin B, et al. Electroconvulsive therapy in drug-induced psychiatric states and neuroleptic malignant syndrome. J ECT 2005; 2: 125-7. pmid:15905757 PubMed
  13. Guinart D, Misawa F, Rubio JM, et al. A systematic review and pooled, patient-level analysis of predictors of mortality in neuroleptic malignant syndrome. Acta Psychiatr Scand 2021; 144: 329-341. pmid:34358327 PubMed
  14. Nielsen RE, Wallenstein Jensen SO, Nielsen J. Neuroleptic malignant syndrome-an 11-year longitudinal case-control study. Can J Psychiatry 2012; 57: 512-8. pmid:22854034 PubMed
  15. Nakamura M, Yasunaga H, Miyata H, et al. Mortality of neuroleptic malignant syndrome induced by typical and atypical antipsychotic drugs: a propensity-matched analysis from the Japanese Diagnosis Procedure Combination database. J Clin Psychiatry 2012; 73: 427-30. pmid:22154901 PubMed
Annonse
Annonse